The conference will explore advancements in ophthalmic treatments and variety of novel drugs, which are showing great clinical trial data. There will also be a specific focus on drug delivery along with advancements in novel technologies. Further key areas will be gene therapy and Artificial Intelligence with developments on the latest drug pipelines and clinical trials.
The conference is co-chaired by
The co-chairs
“The Ophthalmic Drugs conference will bring together expertise from individuals in multiple disciplines of the field. Our packed agenda will offer a series of presentations, through which you will gain insight into new industry developments and clinical trials, innovations in the treatment of rare diseases, regulatory perspectives, and advances in gene therapy.
“As the Co-chairs of this conference, we look forward to personally welcoming you to this must-attend conference in
The full invitation chair letter can be found in the brochure at www.ophthalmicdrugs.com/pr4prcom
Key benefits of attending, include
• Assess new industry directions through the latest data from ophthalmic clinical trials.
• Review advanced techniques in treating age-related diseases of ophthalmology.
• Explore evolving therapeutic potential in undruggable diseases through innovative gene therapies.
• Examine novel methodologies in delivery technologies being used to further the ophthalmic therapeutic field.
• Engage in the regulatory landscape of ophthalmic drugs and key considerations for R&D.
For sponsorship enquiries, contact
For media partnerships and press enquiries, contact
Ophthalmic Drugs
www.ophthalmicdrugs.com/pr4prcom
#OphthalmicDrugs
About SAE Media Group Conferences:
SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on
Contact Information:
+44 (0) 20 7827 6162
Contact via Email
www.ophthalmicdrugs.com/pr4prcom
Read the full story here: https://www.pr.com/press-release/872274
Press Release Distributed by PR.com
Copyright © 2022 PR.com and its licensors
, source